| Literature DB >> 30881626 |
Siddhartha Akasapu1, Aaron B Hinds1, Wyatt C Powell1, Maciej A Walczak1.
Abstract
Thiopeptides are a class of potent antibiotics with promising therapeutic potential. We developed a novel Mo(vi)-oxide/picolinic acid catalyst for the cyclodehydration of cysteine peptides to form thiazoline heterocycles. With this powerful tool in hand, we completed the total syntheses of two representative thiopeptide antibiotics: micrococcin P1 and thiocillin I. These two concise syntheses (15 steps, longest linear sequence) feature a C-H activation strategy to install the trisubstituted pyridine core and thiazole groups. The synthetic material displays promising antimicrobial properties measured against a series of Gram-positive bacteria.Entities:
Year: 2018 PMID: 30881626 PMCID: PMC6383332 DOI: 10.1039/c8sc04885a
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1Selected thiopeptide antibiotics of the D series.
Invention and optimization of MoO2(L)2-catalyzed cysteine cyclodehydration
|
| |||||||
|
| |||||||
| Entry | L | Time | Yield | Entry | L | Time | Yield |
| 1 | None | 16 h | 18% | 7 |
| 16 h | 19% |
| 2 |
| 16 h | 85% | 8 |
| 16 h | 8% |
| 3 |
| 2.5 h | 87% | 9 |
| 16 h | 9% |
| 4 |
| 16 h | 97% | 10 |
| 16 h | 68% |
| 5 |
| 16 h | 98% | 11 |
| 16 h | 62% |
| 6 |
| 16 h | 26% | 12 |
| 16 h | <1% |
Scheme 1(A) Proposed mechanism of Mo-catalysed cyclodehydration (second carboxylate ligand abbreviated for clarity). (B) Selected geometrical parameters of MoO2(X)2 complexes optimized at B3LYP/6-31G(d)/LANL2DZ level of theory. The optimized structure of the thermodynamic complex of MoO2(pic)2, pic = 2-picolinate is presented in the middle of the catalytic cycle.
Scheme 2Synthesis of bottom fragments 25. (a) MoO2(acac)2 (10 mol%), 8b (20 mol%), PhMe, 110 °C, 2.5 h: 18a – 92%, 18b – 98%; (b) DBU, CBrCl3, CH2Cl2, 0 °C, 1 h: 18a – 97%, 18b – 91%; (c) 20, NaHCO3, THF, 0 °C to rt, 16 h then pyridine, TFAA, 0 °C, 20 min, 94%; (d) HCl, 1,4-dioxane, rt, 7 h then 22, HATU, DIPEA, DMF, 0 °C to rt, 1 h, 76%; (e) MsCl, Et3N, CH2Cl2, 0 °C, 1 h then DABCO, Et2NH, 0 °C to rt, CH2Cl2, 16 h, 91%; (f) HCl, 1,4-dioxane, 0 °C to rt, 45 min; (g) Bu2SnO, MeOH, 80 °C, 4 h then LiOH, H2O/THF, 90% (over two steps); (h) HATU, DIPEA, DMF, 0 °C to rt, 2 h: 25a – 72%, 25b – 78%.
Scheme 3Preparation of the top fragment and completion of the syntheses. (a) Pd(OAc)2 (5 mol%), CyJohnPhos (15 mol%), Cs2CO3, DMF, 110 °C, 12 h, 73%; (b) NaOMe, MeOH, –20 to 0 °C, 99%; (c) i – m-CPBA, CH2Cl2, rt, 2 d; ii – POCl3, DMF, 0 °C, CH2Cl2, 97% (over two steps); (d) HCl, 1,4-dioxane, rt, 9 h then 30, HATU, DIPEA, DMF, 0 °C to rt, 2 h, 72%; (e) i – TFA, Et3SiH, CH2Cl2, 0 °C, 1 h then MoO2(acac)2 (10 mol%), PhMe, 110 °C, 13 h; (f) MnO2, CH2Cl2, rt, 24 h, 86% (from 31); (g) 33, PdCl2(PPh3)2 (10 mol%), 1,4-dioxane, 90 °C, 18 h, 97%; (h) NBS, THF, pH 7 phosphate buffer, rt, 1 h, 79%; (i) i – 35, KHCO3, dimethoxyethane, –40 °C to rt, 24 h then TFAA, 2,6-lutidine, dimethoxyethane, –20 °C, 20 h, 85%; (j) Me3SnOH, (CH2Cl)2, 80 °C, 20 h, 73%; (k) HCl, 1,4-dioxane, 0 °C to rt, 30–45 min: 38a – 90%, 38b – 53%; (l) HATU, DIPEA, DMF, 0 °C to rt, 2 h: 39a – 82%, 39b–53%; (m) NaOH, MeOH, 0 °C to rt, 2 h then 43, HATU, DIPEA, DMF, 0 °C to rt, 2 h; (n) MsCl, Et2NH, CH2Cl2 0 °C to rt, 15 min then DABCO, Et2NH, CH2Cl2, 0 °C to rt, 2.5 d; (o) HCl, 1,4-dioxane, rt, 16 h then PyAOP, DIPEA, DMF, –20 °C, 30 min, 22% (for 1 from 39a); (p) TBAF, THF, 0 °C, 1–2 h, 15% (for 2 from 39b).
Minimum inhibitory concentration (MIC) values for micrococcin P1 and thiocillin I
| Isolate | MIC (μg mL–1) | ||||
| 1 | 2 | Vancomycin | Ciprofloxacin | ||
|
| ATCC 29213 | 4 | 2 | 1 | 0.5 |
| 1974149 | 2 | 2 | 0.5 | 0.25 | |
| 1974148 | 8 | 2 | 1 | >16 | |
|
| 1674621 | 1 | 0.5 | 0.5 | 1 |
| 1674614 | 1 | 0.5 | >16 | >16 | |
|
| ATCC 6633 | >16 | 4 | 0.25 | 0.06 |
|
| 1744264 | 1 | 0.5 | 0.5 | 0.25 |